Abstract:Nucleic acid-based therapy has emerged as a revolutionary methodology for treatment of the diseases related to protein dysfunction; however, lack of systemically applicable synthetic delivery systems limits its current usage in local applications, particularly for DNA-based therapy with regard to the poor bioavailability in the systemic administrations. To overcome this obstacle, we compiled multiple chemistry-based strategies into the manufacture of the gene delivery formulations to pursue improved tolerability of DNA to the enzymatic degradation in the biological milieu and prolonged retention in the systemic circulation. Here, we constructed a distinctive multilayered functional architecture: plasmid DNA (pDNA) was electrostatically complexed with cationic poly(lysine) (polyplex) as the interior pDNA reservoir, which was further cross-linked by redox-responsive disulfide cross-linking to minimize the occurrence of polyplex disassembly through exchange reaction with the biological charged,components. Still, the pDNA reservoir was spatially protected by a sequential thermoresponsive poly(N-isopropylacrylamide) palisade as the intermediate barrier and a biocompatible hydrophilic poly(ethylene glycol) (PEG) shell with the aim of preventing the accessibility of the biological species, particularly the nuclease degradation to the pDNA payload. Subsequent investigations validated the utilities of these strategies in accomplishing prolonged blood retention. In an attempt to apply this method for tumor therapy, ligand cyclic (Arg-Gly-Asp) peptide was attached at the distal end of PEG, validating prompted tumor-targeted delivery and gene expression of the loaded antiangiogenic gene at the targeted tumor cells and accordingly exerting antiangiogenesis of the tumors for abrogation of tumor growth. Together with its excellent safe profile, the proposed formulation suggests potential utility as a practical gene delivery system for treatment of intractable diseases.

Prodrug-type antisense oligonucleotides with enhanced nuclease stability and anti-tumour effects

Synthesis, Stability, and Anti-Tumour Activity of a New Category of “Stapled” Antisense Oligonucleotides with Stimuli-Responsive Feature

Anisamide-conjugated hairpin antisense oligonucleotides prodrug co-delivering doxorubicin exhibited enhanced anticancer efficacy

Synthesis, Biophysical Properties, and Antitumor Activity of Antisense Oligonucleotides Conjugated with Anisamide

A responsive disulfide bond switch aptamer prodrug exhibiting enhanced stability and anticancer efficacy

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Synthesis and evaluation of antisense oligonucleotides prodrug with G-quadruplex assembly and lysosome escape capabilities for oncotherapy

Synthesis and Evaluation of 4′‐C‐(S) and 4′‐C‐(R)‐2‐Aminopropoxy−Thymidine‐Modified DNAs for Thermal Stability, RNase H Digestion, and Nuclease Resistance

Synthesis, Physicochemical and Biological Properties of Oligonucleotides Incorporated with Amino-Isonucleosides

Going nuclear: Improved antisense oligonucleotide activity through conjugation with a nuclear importer

Theranostic DNA nanostructure based on phenotype-specific activation of antisense oligonucleotides

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

Studies on drug targeting to nucleic acids

Structural Optimization and Additional Targets Identification of Antisense Oligonucleotide G3139 Encapsulated in a Neutral Cytidinyl-Lipid Combined with a Cationic Lipid in Vitro and in Vivo

Therapeutic Oligonucleotides: State of the Art

Opportunities and challenges for antisense oligonucleotide therapies

ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION

Delivery and controllable release of anti-sense DNA based on frame-guided assembly strategy

Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2′,4′-BNA/LNA with 9-(aminoethoxy)phenoxazine

Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation

Modified ASO Conjugates Encapsulated with Cytidinyl/cationic Lipids Exhibit More Potent and Longer-Lasting Anti-Hcc Effects